NH TherAguix , a Phase 2 biotech company, has developed an innovative nano drug AGuIX® to improve cancer treatment by radiotherapy to treat tumours and metastases. 
Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential.
AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereo-radiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA).
NH TherAguix was established in 2015 after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radioenhancement effect. Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.

Arbevel

Omnes Capital

Supernova Invest

Bpifrance

NH TherAguix

NH TherAguix announced today the appointment of Jean-Philippe Del as Chief Financial Officer. Welcome to the team!

To read the Press Release, click here: https://lnkd.in/ecvmzUW3

#Aguix #Nanodrug #Nanodrugs #Clinicalresearch #Cancer #Tumours #Metastases #Brainmetastases #Brainmets #Glioblastoma #Pancreaticcancer #Lungcancer #Radiotherapy #Radioenhancer #NHTherAGuix #NHT #Team #Newsupdate #Radiosensitizer #Gadolinium

NH TherAguix announces the publication of promising preclinical results of AGuIX® in combination with targeted radioligand therapies (TRT) in the Journal of Nuclear Medicine (October 2023).

More information: https://lnkd.in/eTnBCYE5

#NHTherAguix #AGuIX #Radiotherapy #Radioenhancer #Nanodrug #Clinicalresearch #TRT #Cancer #Tumors #Metastases

Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis!

More information: https://lnkd.in/eYAhc_Ep

#NHTheraguix #NHT #CHUGA #Aguix #Nanodrug #CancerResearch #Brainmetastasis #Metastasis #Glioblastoma #Nanorad2

A Grateful Visit to Our Valued Partners at Harvard Medical School and Dana Farber Cancer Institute! 

We recently had the privilege of visiting the esteemed teams led by Ayal Aizer, Jonathan Leeman and Ross Berbeco at Harvard Medical School and the Dana-Farber Cancer Institute. Our collaboration and their pivotal role in advancing the phase II clinical trials of our lead drug candidate, AGuIX®, have been instrumental in shaping the future of cancer therapeutics.

The insights gained during our visit were not only enlightening but also reaffirmed our commitment to pioneering solutions in the fight against cancer. Witnessing the dedication and expertise of these brilliant minds firsthand was truly inspiring. Their collaborative spirit and relentless pursuit of innovation align perfectly with NH TherAguix's mission to make a meaningful impact on patient lives.

I extend my heartfelt gratitude to the entire team at Harvard Medical School and Dana Farber Cancer Institute for their warm welcome, insightful discussions, and invaluable contributions to our shared journey. Together, we're pushing the boundaries of what's possible in cancer treatment.

Our partnership remains a cornerstone in our pursuit of advancing AGuIX® towards its full potential. I am excited about the continued collaboration and the positive impact we can create together.

#NHTheraguix #Aguix #Nanodrug #CancerResearch #Collaboration #Innovation #HarvardMedicalSchool #DanaFarberCancerInstitute #Gratitude #Biotech

NH TherAguix is hiring a Drug Product Manager!!

More information: https://lnkd.in/eVvzQKPB

#NHTherAguix #AGuIX #NHT #Nanodrug #DrugProductManager #ProductManager #Nanomedicine #CMC #Chemistry

NH TherAguix and centre jean perrin in Clermont-Ferrand announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included!

#NhTheraguix #NHT #Centrejeanperrin #Glioblastoma #Glioblastome #Aguix #Cancer 

https://lnkd.in/eQVFPa8A

Congratulations Léna Carmès and the team!!

Appointment of Vincent Carrère as CEO of NH TherAguix in BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle

#NHTherAguix #NHT #AGuIX #Nanodrug #Nanodrugs #Clinicalresearch #Cancer #Tumours #Metastases #Brainmetastases #Brainmets #Glioblastoma #Pancreaticcancer #Lungcancer #Radiotherapy #Radioenhancer #Radiosensitizer #Gadolinium

NH TherAguix announced today the appointment of Vincent Carrère as Chief Executive Officer. Welcome to the team!

To read the press release, click here: https://lnkd.in/e6zYvHcv

#NHTherAguix #NHT #NHTx #Nanodrug #Nanodrugs #Clinicalresearch #Cancer #Tumours #Metastases #Brainmetastases #Brainmets #Glioblastoma #Pancreaticcancer #Lungcancer #Radiotherapy #Radioenhancer #Team #Newsupdate #Radiosensitizer #AGuIX #Gadolinium

Apexian Pharmaceuticals is a biopharmaceutical company focused on developing novel compounds for the treatment of cancer.

Apexian Pharmaceuticals

Peloton Therapeutics is a biopharmaceutical company specializing in the development of small molecule drugs for the treatment of cancer and other diseases.

Peloton Therapeutics

Urogen Pharma is a biopharmaceutical company focused on developing and commercializing innovative solutions for urological and oncological conditions.

Urogen Pharma

Lotus Tissue Repair is a biotechnology company dedicated to developing novel therapies for the treatment of various diseases, including cancer.

Lotus Tissue Repair

Emmaus Life Sciences is a biopharmaceutical company committed to developing and commercializing innovative treatments for rare and orphan diseases, including cancer.

Emmaus Life Sciences

Tetherex is a company focused on developing innovative therapies for various medical conditions, including cancer.

Tetherex

Medivir is a biopharmaceutical company specializing in the development of innovative treatments for infectious diseases and cancer.

Medivir

Shanghai Henlius Biotech is a biopharmaceutical company focused on the development and commercialization of innovative biologics for the treatment of various diseases, including cancer.

Shanghai Henlius Biotech

Cullgen is a biotechnology company dedicated to developing novel therapies for the treatment of cancer and other related conditions.

Cullgen

Gilead Sciences Inc is a research-based biopharmaceutical company focused on the development of innovative therapies for life-threatening diseases, including cancer.

Gilead Sciences Inc

Les Laboratoires Servier SAS is a global pharmaceutical company dedicated to the research, development, and commercialization of innovative treatments for various diseases, including cancer.

Les Laboratoires Servier SAS

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development of therapies for rare genetic diseases, including cancer.

BioMarin Pharmaceutical Inc

Nanobiotix SA is a nanomedicine company focused on the development of innovative therapies for cancer treatment using nanotechnology.

Nanobiotix SA

NH TherAguix is a biopharmaceutical company focused on the development of innovative drugs for radiotherapy and imaging of cancer, leveraging the radiosensitization effect of AGuIX®.

news impact assignment basic	general
public peers	general	Jul 3, 2024 4:51 PM	c2f446b0
news daily refresh	general	Sep 2, 2024 12:10 PM	0a1b9f94
news processing daily refresh	general	Sep 2, 2024 9:22 AM	05c1d093
news impact assignment daily	general	Sep 2, 2024 9:23 AM	978280ae
news processing basic	general	Jul 3, 2024 4:52 PM	dd80131c
company summary	general	Aug 31, 2024 7:59 AM	102c06f3
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	76ce7fba
crunchbase profile	general
li profile	general	Jul 3, 2024 4:51 PM	c9334c3a
translate crunchbase fundingrounds	general
peers	general	Jul 3, 2024 4:51 PM	3df094c0
news basic	general	Jul 3, 2024 4:51 PM	58d3c928
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NHTHERAGUIX

NH TherAguix